Manufacturer of Controlled Substances; Notice of Registration; Apertus Pharmaceuticals, 69134 [2013-27487]
Download as PDF
<![CDATA[
69134
Federal Register / Vol. 78, No. 222 / Monday, November 18, 2013 / Notices
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
DEPARTMENT OF LABOR
Drug Enforcement Administration
Drug Enforcement Administration
Office of the Secretary
Manufacturer of Controlled
Substances; Notice of Registration:
AMPAC Fine Chemicals, LLC.
Manufacturer of Controlled
Substances; Notice of Registration;
Apertus Pharmaceuticals
By Notice dated July 23, 2013, and
published in the Federal Register on
July 31, 2013, 78 FR 46372, AMPAC
Fine Chemicals, LLC., Highway 50 and
Hazel Avenue, Building 05001, Rancho
Cordova, California 95670, made
application by renewal to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of the following basic
classes of controlled substances:
By Notice dated July 23, 2013, and
published in the Federal Register on
July 31, 2013, 78 FR 46372, Apertus
Pharmaceuticals, 331 Consort Drive, St
Louis, Missouri 63011, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Current
Population Survey—Displaced Worker,
Job Tenure, and Occupational Mobility
Supplement
Drug
Schedule
Drug
mstockstill on DSK4VPTVN1PROD with NOTICES
Methylphenidate (1724) ................
Thebaine (9333) ...........................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
II
II
II
II
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
The company is a contract
manufacturer. In reference to Poppy
Straw Concentrate the company will
manufacture Thebaine intermediates to
sell to its customers for further
manufacture. No other activity for this
drug code is authorized for registration.
No comments or objections have been
received. Comments and requests for
hearings on applications to import
narcotic raw material are not
appropriate. 72 FR 3417 (2007).
DEA has considered the factors in 21
U.S.C. 823(a) and determined that the
registration of AMPAC Fine Chemicals,
LLC., to manufacture the listed basic
classes of controlled substances is
consistent with the public interest at
this time.
DEA has investigated AMPAC Fine
Chemicals, LLC., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: November 4, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
for distribution to their customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Apertus Pharmaceuticals to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time.
DEA has investigated Apertus
Pharmaceuticals to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 5, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–27487 Filed 11–15–13; 8:45 am]
BILLING CODE 4410–09–P
Jkt 232001
The Department of Labor
(DOL) is submitting the Bureau of Labor
Statistics (BLS) sponsored information
collection request (ICR) titled, ‘‘Current
Population Survey—Displaced Worker,
Job Tenure, and Occupational Mobility
Supplement,’’ to the Office of
Management and Budget (OMB) for
review and approval for reinstatement,
without change, in accordance with the
Paperwork Reduction Act of 1995
(PRA), 44 U.S.C. 3501 et seq.
DATES: Submit comments on or before
December 18, 2013.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov Web site at https://
www.reginfo.gov/public/do/
PRAViewICR?ref_nbr=201308-1220-001
(this link will only become active on the
day following publication of this notice)
or by contacting Michel Smyth by
telephone at 202–693–4129 (this is not
a toll-free number) or sending an email
to DOL_PRA_PUBLIC@dol.gov.
Submit comments about this request
by mail or courier to the Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for DOL–BLS,
Office of Management and Budget,
Room 10235, 725 17th Street NW.,
Washington, DC 20503; by Fax: 202–
395–6881 (this is not a toll-free
number); or by email: OIRA_
submission@omb.eop.gov. Commenters
are encouraged, but not required, to
send a courtesy copy of any comments
by mail or courier to the U.S.
Department of Labor-OASAM, Office of
the Chief Information Officer, Attn:
Information Policy and Assessment
Program, Room N1301, 200 Constitution
Avenue NW., Washington, DC 20210; or
by email: DOL_PRA_PUBLIC@dol.gov.
FOR FURTHER INFORMATION: Contact
Michel Smyth by telephone at 202–693–
4129 (this is not a toll-free number) or
by email at DOL_PRA_PUBLIC@dol.gov.
SUMMARY:
This ICR
seeks to reinstate a previously approved
SUPPLEMENTARY INFORMATION:
BILLING CODE 4410–09–P
17:33 Nov 15, 2013
Notice.
Authority: 44 U.S.C. 3507(a)(1)(D).
[FR Doc. 2013–27484 Filed 11–15–13; 8:45 am]
VerDate Mar<15>2010
II
II
II
II
ACTION:
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 78, Number 222 (Monday, November 18, 2013)]
[Notices]
[Page 69134]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-27487]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Apertus Pharmaceuticals
By Notice dated July 23, 2013, and published in the Federal
Register on July 31, 2013, 78 FR 46372, Apertus Pharmaceuticals, 331
Consort Drive, St Louis, Missouri 63011, made application by renewal to
the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances to make reference standards for distribution to
their customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and determined that the registration
of Apertus Pharmaceuticals to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time.
DEA has investigated Apertus Pharmaceuticals to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR
1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: November 5, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-27487 Filed 11-15-13; 8:45 am]
BILLING CODE 4410-09-P
